How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

OpenAI and Anthropic researchers are urging a slowdown in advanced AI development over catastrophic-risk concerns. They cite ...

Alarm grew after a researcher resigned, warning that the “people building AI earnestly believe that it could kill us all by ...

Anthropic CEO Dario Amodei is calling on artificial intelligence companies to slow the development of their most advanced models, a proposal that has drawn support from several other industry leaders.

Apparently, folding is only Apple's warm-up stretch. Yesterday, Apple secured US patent 12,730,478 B2 detailing a stretchable ...

The researcher warned that AI leaders sincerely believe the technology could kill all of humanity by the decade’s end, saying it’s not a ’marketing stunt.’ ...

'We really do earnestly believe AI could kill all humans!' ...